WeVote
Log In

Bill

Bill

SJR 7

DIRECTING THE STATE EMPLOYEE BENEFITS COMMITTEE AND THE SECRETARY OF HUMAN RESOURCES TO ENGAGE WITH INDEPENDENT CONSULTANTS AND OTHER SUPPLY CHAIN TACTICS FOR COST CONTAINMENT OF PRESCRIPTION DRUGS FOR STATE EMPLOYEES AND RETIREES’ INSURANCE PROGRAMS.

153rd General Assembly (2025-2026) Introduced by Frank Cooke and 10 co-sponsors

Delaware directs state employee benefits officials to hire consultants and use supply chain strategies to reduce prescription drug costs for state workers and retirees.

Signed by Governor
0
WeVote Research Nonpartisan
Bill Summary · SJR 7

Legislative bill overview

SJR 7 directs Delaware's State Employee Benefits Committee and Secretary of Human Resources to hire independent consultants and implement supply chain strategies to reduce prescription drug costs for state employees and retirees. The bill has already been signed into law as of August 2025, making this a directive for executive action rather than a new regulatory framework.

Why is this important

Prescription drug costs represent a significant portion of health insurance expenses for state employee benefit programs. By mandating engagement with outside consultants and supply chain optimization, the state aims to control healthcare spending while maintaining coverage for its workforce—savings that could redirect funds to other state priorities or reduce premium increases for employees and retirees.

Potential points of contention

  • Consultant costs vs. savings: Hiring independent consultants to analyze supply chains requires upfront spending; the bill does not specify whether projected savings must exceed consultant fees or include cost-benefit analysis requirements.
  • Pharmaceutical industry relationships: Supply chain tactics (such as preferred formularies or manufacturer negotiations) may affect which medications are prioritized, potentially limiting employee choice or creating access questions for certain drugs.
  • Implementation scope and timeline: The bill provides a directive but no explicit deadline, benchmarks, or performance metrics, leaving unclear how aggressively cost containment should be pursued or how success will be measured.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.